AKT1 and breast cancer: Camizestrant (AZD9833) is a next‐generation oral SERD that has demonstrated encouraging results in preclinical ER+ BC models, both as monotherapy and in combination with CDK4/6 or PI3K/Akt/mTOR inhibitors, effectively addressing endocrine and CDK4/6 inhibitor resistance [682].